Muscle Fatigue and Carbonic Anhydrase Inhibitors

University of British Columbia logo

University of British Columbia

Status and phase

Completed
Phase 4

Conditions

Hypoxia

Treatments

Drug: Methazolamide
Other: Placebo
Drug: Acetazolamide

Study type

Interventional

Funder types

Other

Identifiers

NCT02758470
H16-00896

Details and patient eligibility

About

The objective of this research is to assess the effects of acetazolamide and methazolamide on respiratory and limb muscle fatigue development. A fatiguing protocol will be conducted for the respiratory and plantar flexor muscles and the difference in pressure/torque produced by supramaximal nerve stimulation used to assess muscle fatigue between conditions.

Enrollment

13 patients

Sex

Male

Ages

18 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age: 18-40 years.
  • Regularly physically active
  • Male

Exclusion criteria

  • current or ex-smokers
  • pulmonary function <80% of predicted
  • esophageal tumour or ulcer
  • have had recent (<6 months) musculoskeletal injury or any surgery to the lower leg
  • have contraindications to carbonic anhydrase inhibitors (eg. severe or absolute glaucoma, adrenocortical insufficiency, hepatic insufficiency, renal insufficiency, sulfa allergy or an electrolyte imbalance such as hyperchloremic acidosis)
  • are obese (BMI >30 Kg/m2)
  • taking diuretics, blood thinners, or anti-platelet drugs.

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

13 participants in 3 patient groups, including a placebo group

Acetazolamide
Experimental group
Description:
Participants will be dosed 250mg acetazolamide (p.o.) three times per day for two days prior to and a single dose on the morning of the experimental day.
Treatment:
Drug: Acetazolamide
Methazolamide
Experimental group
Description:
Participants will be dosed 100mg Methazolamide (p.o.) two times per day separated by a placebo dose for two days prior to and a single dose on the morning of the experimental day. The placebo dose is used to match the timing and number of pills taken between all arms of the study.
Treatment:
Drug: Methazolamide
Placebo
Placebo Comparator group
Description:
Participants will take three placebo pills per day for two days prior to and a single dose on the morning of the experimental day.
Treatment:
Other: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems